张路，南方科技大学生物医学工程系副教授，博士生导师，国家重点研发首席科学家，海外优青。2016年博士毕业于中山大学化学与化学工程学院（师从帅心涛教授），同年赴美加入加州大学戴维斯分校医学中心开展博士后研究（师从组合化学及分子医学领域权威专家Kit S. Lam讲席教授）。2021年8月回国加入南方科技大学生物医学工程系，组建纳米生物医学 (Nano Biomedicine，NBM) 课题组，任课题组组长（独立PI）。

      课题组科研围绕“生物医用纳米材料活体仿生组装、结构调控与癌症诊疗的关系”进行系统研究，涉及化学、材料、生物、医学和工程交叉学科，研究内容主要包括纳米药物精准递送、活体原位仿生自组装、纳米药剂临床转化应用等。

      目前主持国家重点研发计划“合成生物学”重点专项（2023）、国家自然科学基金优秀青年科学基金项目（海外）、国家自然科学基金面上项目（2022）、广东省基础与应用基础研究基金自然科学基金面上项目（2024）、深圳市自然科学基金面上项目（2022）等。

      以通讯及第一作者在Nature Nanotechnology、Nature Communications、Nano Letters、ACS Nano、Biomaterials、Advanced Functional Materials、Hepatology、Theranostics等高水平期刊上发表多篇SCI论文，研发的纳米技术及药剂已获多项国际及国内专利授权，并被FDA批准正在美国开展多项纳米药剂临床转化实验。

工作 & 教育背景

2022.12-至今             副教授（PI）    南方科技大学       生物医学工程系

2021.08-2022.12         助理教授（PI）    南方科技大学       生物医学工程系

2016.09-2021.07   博士后, 美国加州大学戴维斯分校，医学中心，生物化学与分子医学系

                              导师：Kit S Lam教授 (组合化学和分子医学领域权威专家)

2011.09-2016.06     博士 (硕博连读)，中山大学，化学与化学工程学院

                               导师：帅心涛教授 (国家杰出青年科学基金获得者)

研究方向

       针对临床癌症精准成像诊断和高效治疗面临的难题开展工作，围绕“生物医用纳米材料活体仿生组装、结构调控与癌症诊疗的关系”科学问题进行系统研究，牢牢扎根在化学、材料、生物、医学和工程交叉学科研究的前沿，选用生物相容性好、人体安全性高的多肽或聚氨基酸为基础生物材料，研究内容聚焦三个方面：

1） 纳米药物精准递送：建立精准调控纳米结构尺寸的新方法，提升纳米药物体内稳定性、灵敏性，提出AIE/ACQ荧光比率新策略，实现纳米结构组装与解离动态监测，解决如何将纳米药更精准、更高效、更灵敏地送到癌症病灶部位；

2） 活体原位仿生自组装：在动物活体环境下，发展膜蛋白特异性的β折叠新多肽材料，提出纳米材料纤维化组装进行无药物治疗新策略，建立重塑活体细胞表面的新型生物技术平台，在癌症病灶部位，基于纳米材料原位自组装形貌转变，提升纳米药物及材料的体内生物利用度；

3） 纳米药剂临床转化应用：推进纳米药剂的临床转化应用研究，开展基础科研与临床科学结合的系统研究。

代表性成果

文章

1) Lu Zhang#, Di Jing#, Nian Jiang, Tatu Rojalin, Christopher M. Baehr, Dalin Zhang, Wenwu Xiao, Yi Wu, Zhaoqing Cong, Jian Jian Li, Yuanpei Li, Lei Wang*, Kit S. Lam*. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nature Nanotechnology 2020, 15(2), 145-153. (IF: 40.523)

2) Chunping Mao, Fuan Deng, Wanning Zhu, Leiming Xie, Yijun Wang, Guoyin Li, Xingke Huang, Jiahui Wang, Yue Song, Ping Zeng, Zhenpeng He, Jingnan Guo, Yao Suo, Yujing Liu, Zhuo Chen, Mingxi Yao, Lu Zhang*, Jun Shen*. In Situ Editing of Tumour Cell Membranes Induces Aggregation and Capture of PD-L1 Membrane Proteins for Enhanced Cancer Immunotherapy. Nature Communications 2024, 15, 9723. (IF: 14.7)

3) Yichi Chen, Yijun Wang, Ruotian Zhang, Fengyi Wang, Xin Lin, Tong Wang, Wenyuan Zhang, Fuan Deng, Bolin Wu, Haitao Shang, Wen Cheng*, Lu Zhang*. In Situ Transformable Fibrillar Clusters Disrupt Intracellular Copper Metabolic Homeostasis by Comprehensive Blockage of Cuprous Ions Efflux. Small 2024, 2406802. (IF: 13.0)

4) Wenyuan Zhang, Liejing Lu, Zheng Zhu, Fuan Deng, Wenchang Zhang, Fengyi Wang, Ping Zeng, Haonan Shi, Tong Wang, Yichi Chen, Yue Song, Yiping Liu, Tianze Kang, Kai Li, Jie Mao, Zhengwei Liu*, Lu Zhang*. A Manganese-Based Nanodriver Coordinates Tumor Prevention and Suppression through STING Activation in Glioblastoma. Adavnced Hralthcare Materials 2024, 202400421. (IF: 10.0)

5) Wenyuan Zhang, Jianrui Zhang, Yijun Wang, Senyao Wang, Yitian Wu, Wenchang Zhang, Minghui Wu, Li Wang, Guoheng Xu, Fuan Deng, Wenchao Liu, Zhengwei Liu*, Lu Chen*, Kai Xiao*, Lu Zhang*. In Vitro Detection of S100B and Severity Evaluation of Traumatic Brain Injury Based on Biomimetic Peptide-Modified Nanochannels. Small 2023, 2306809. (IF: 13.3)

6) Di Jing, Nian Jiang, Fengyi Wang, Chunping Mao, Shujun Han, Pui Yan Ho, Wenwu Xiao, Yuanpei Li, Jian-Jian Li, Lu Zhang*(co-corresponding), Kit S Lam*. Nanoradiosensitizer with good tissue penetration and enhances oral cancer radiotherapeutic effect. Biomaterials 2022, 289, 121769. (IF: 15.304)

7) Lu Zhang*(co-corresponding), Ruonan Bo, Yi Wu, Longmeng Li, Zheng Zhu, Ai-Hong Ma, Wenwu Xiao, Yanyu Huang, Tatu Rojalin, Xingbin Yin, Chunping Mao, Fengyi Wang, Yongheng Wang, Hongyong Zhang, Kelmen E. Low, Kiana Lee, Yousif Ajena, Di Jing, Dalin Zhang, Christopher M. Baehr, Ruiwu Liu, Lei Wang*, Yuanpei Li*, Kit S. Lam*. A programmable bispecific nano-immuno-engager captures T cells and reprograms tumor microenvironment. Nano Letters 2022, 22 (17), 6866-6876. (IF: 12.262)

8) Zhiqin Zhang, Kaixin Wang, Manting Liu, Panxiang Hu, Yuchen Xu, Dongge Yin, Yuchang Yang, Xiaoxv Dong, Changhai Qu, Lu Zhang* (co-corresponding), Jian Ni*, Xingbin Yin*. Phototherapeutic effect of transformable peptides containing pheophorbide a on colorectal cancer. Drug Delivery 2022, 29(1), 1608-1619. (IF: 6.819)

9) Lu Zhang, Yi Wu, Xingbin Yin, Zheng Zhu, Tatu Rojalin, Wenwu Xiao, Dalin Zhang, Yanyu Huang, Longmeng Li, Christopher M. Baehr, Xingjian Yu, Yousif Ajena, Yuanpei Li, Lei Wang* and Kit S. Lam*. Tumor Receptor-Mediated In Vivo Modulation of the Morphology, Phototherapeutic Properties, and Pharmacokinetics of Smart Nanomaterials. ACS Nano 2021, 15(1), 468-479. (IF: 18.027)

10) Hao Wu#, Lu Zhang#(co-first), Jinfan Yang, Ruonan Bo, Hongxu Du, Kai Lin, Dalin Zhang, Mythili Ramachandran, Yingbin Shen, Yangxi Xu, Xiangdong Xue, Zhao Ma, Aaron Raymond Lindstrom, Randy Carney, Tzu-Yin Lin, Yuanpei Li*. Rotatable Aggregation-Induced-Emission/Aggregation Caused-Quenching Ratio Strategy for Real-Time Tracking Nanoparticle Dynamics. Advanced Functional Materials 2020, 30(15), 1910348. (IF: 19.924)

11) Lu Zhang#, Hao Wu#, Yuanpei Li*, Kit S. Lam*. Nanoengineered Biomaterials for Advanced Drug Delivery (11th chapter) Reversible Cross-Linked Polymeric Micelles for Drug Delivery. Elsevier, 2020, 243-260. (Academic Treatise)

12) Mengru Cai, Liuying Qin, Longtai You, Yu Yao, Huimin Wu, Zhiqin Zhang, Lu Zhang* (co-corresponding), Xingbin Yin*, Jian Ni*. Functionalization of MOF-5 with Mono-Substituents: Effects on Drug Delivery Behavior. RSC Advances 2020, 10(60), 36862-36872. (IF: 4.036)

13) Lu Zhang, Yanyu Huang, Aaron Raymond Lindstrom, Tzu-Yin Lin, Kit S Lam, Yuanpei Li*. Peptide-based materials for cancer immunotherapy. Theranostics 2019, 9(25), 7807-7825. (IF: 11.6)

14) Lu Zhang#, Tinghui Yin#, Bo Li, Rongqin Zheng*, Chen Qiu, Kit S. Lam*, Qi Zhang, Xintao Shuai*. Size-Modulable Nanoprobe for High-Performance Ultrasound Imaging and Drug Delivery against Cancer. ACS Nano 2018, 12(4), 3449-3460. (IF: 18.027)

15) Lu Zhang#, Di Jing#, Lei Wang, Yuan Sun, Jian Jian Li, Brianna Hill, Fan Yang, Yuanpei Li*, Kit S. Lam*. Unique Photochemo-Immuno-Nanoplatform against Orthotopic Xenograft Oral Cancer and Metastatic Syngeneic Breast Cancer. Nano Letters 2018, 18(11), 7092-7103. (IF: 12.262)

16) Hao Wu#, Lu Zhang#(co-first), Yuanpei Li*; Kit S. Lam*; Stimuli-Responsive Materials in Theranostics. Royal Society of Chemistry, 2018. (Academic Treatise)

17) Yu Guo#, Jing Wang#, Lu Zhang#(co-first), Shunli Shen#, Ruomi Guo, Yang Yang*, Wenjie Chen, Yiru Wang, Guihua Chen*, Xintao Shuai*. Theranostical Nanosystem-Mediated Identification of An Oncogene and Highly Effective Therapy in Hepatocellular Carcinoma. Hepatology 2016, 63(4), 1240-1255. (IF: 17.298)

18) Lu Zhang#, Hong Xiao#, Jingguo Li, Du Cheng*, Xintao Shuai*. Co-delivery of doxorubicin and arsenite with reduction and pH dual-sensitive vesicle for synergistic cancer therapy. Nanoscale 2016, 8(25), 12608-12617. (IF: 8.307)

19) Pei-Pei Yang#, Yi-Jing Li#, Yan Cao#, Lu Zhang, Jia-Qi Wang, Zi-Wei Lai, Kuo Zhang, Diedra Shorty, Wenwu Xiao, Hui Cao, Lei Wang*, Hao Wang*, Ruiwu Liu*, Kit S. Lam*. Rapid discovery of self-assembling peptides with one-bead one-compound peptide library. Nature Communications 2021, 12, 4494. (IF: 17.694)

20) Christopher M. Baehr, Lu Zhang, Yi Wu, Andras Domokos, Wenwu Xiao, Lei Wang, Kit S.Lam*. Transformable amyloid-beta mimetic peptide amphiphiles for lysosomal disruption in non-small cell lung cancer. Biomaterials 2021, 277, 121078. (IF: 15.304)

21) Zhaoqing Cong, Lu Zhang, Si-Qi Ma, Kit S.Lam, Fei-Fei Yang*, YongHong Liao*. Size-Transformable Hyaluronan Stacked Self-Assembling Peptide Nanoparticles for Improved Transcellular Tumor Penetration and Photo-Chemo Combination Therapy. ACS Nano 2020, 14(2), 1958-1970. (IF: 18.027)

22) Christopher M. Baehr，Lu Zhang, Kit S. Lam*. Abstract 1740: Transformable amyloid-beta mimetic peptide amphiphiles for lysosomal disruption and cisplatin sensitization in non-small cell lung cancer. Cancer Research, 2020. (IF: 11.2)

23) Hong Xiao, Jin He, Xiaoxia Li, Bo Li, Lu Zhang, Yong Wang*, Du Cheng, Xintao Shuai*. Polymeric Nanovesicles as Simultaneous Delivery Platforms with Doxorubicin Conjugation and Elacridar Encapsulation for Enhanced Treatment of Multidrug-Resistant Breast Cancer. Journal of Materials Chemistry B 2018, 6(45), 7521-7529. (IF: 7.571)

24) Yi Huang, Xiaoxia Li, Lu Zhang, Xiaoyan Chen, Chengbo Liu, Jingqin Chen, Yong Wanga*, XinTao Shuai. Multifunctional Nanoplatform Based on pH-responsive Micelle Coated with Discontinuous Gold Shell for Cancer Photothermo-chemotherapy and Photoacoustic Tomography. Chinese Journal of Polymer Science, 2018, 36, 1139-1149. (IF: 3.815)

25) Jingguo Li, Lu Zhang, Yujie Lin, Hong Xiao, Mingxiang Zuo, Du Cheng, Xintao Shuai*. A pH-Sensitive Prodrug Micelle Self-Assembled from MultiDoxorubicin-Tailed Polyethylene Glycol for Cancer Therapy. RSC Advances. 2016, 6(11), 9160-9163. (IF: 4.036)

26) Faming Gong, Zuoquan Zhang, Xiaodong Chen, Lu Zhang, Xingsu Yu, Qihua Yang, Xintao Shuai, Biling Liang*, Du Cheng*. A dual ligand targeted nanoprobe with high MRI sensitivity for diagnosis of breast cancer[J]. Chinese Journal of Polymer Science, 2014, 32(3), 321-332. (IF: 3.815)

专利

1) Kit S. Lam, Lu Zhang; Cyanine-based telodendrimers and uses for treating cancer, 2020-5-3, WIPO, PCT/US2019/049080

2) Kit S. Lam, Lu Zhang; Smart peptides and transformable nanoparticles for cancer immunotherapy, 2021-2-18, WIPO, PCT/US2020/046495

3) 罗智；李金娜·哈比布利纳；张宇航；张路；姚明曦；李喆；一种液态金属墨水及其制备方法和应用，2024-07-17，2024109674906

4) 鲁敬雄；张路；曹玲燕；杜咏轩；一种DNA水凝胶及其制备方法，2024-08-23，2024111689897

5) 鲁敬雄；张路；曹玲燕；杜咏轩；一种用于核酸检测的 DNA 水凝胶传感器及其制备方法，2024-08-23，202411169049X

6) 张路；沈君；毛椿平；一种用于结合PD-L1的多肽纳米材料及其制备方法与应用，2023-10-13，CN202310758599.4

7) 帅心涛，张路，邱晨，黄毅，左明祥，程度；一种pH与温度双重敏感性的纳米囊泡及其制备方法和应用，2016-07-12，CN201610548026.9

临床转化应用

       已开发多种 GMP 及 GLP 级别的树枝状大分子聚合物包载化疗药和免疫药物的纳米药剂, 化疗药 (Doxorubicin, Paclitaxel 等)，免疫药物(Resiquimod, Imiquimod等)；并在美国获准应用于鼠、兔、猫和狗等动物的膀胱癌、口腔癌、卵巢癌和乳腺癌等模型的临床前研究。

主持科研基金项目  

1) 广东省基础与应用基础研究基金自然科学基金面上项目（2024）

2) 国家重点研发计划“合成生物学”重点专项（2023)

3) 国家自然科学基金优秀青年科学基金项目（海外2022）

4) 国家自然科学基金面上项目（2022）  

5) 深圳市自然科学基金面上项目（2022）

曾主持或参与项目

1) National Cancer Institute (NCI), 1R01CA247685-01, HER2 targeting transformable nanotherapeutic platform against HER2+ cancers, 2020.02-2025.01, $572,096 (Each year).

2) Department of Defense (DOD), W81XWH-19-1-0204, Delivery of targeting nano-photo-imiquimod to greatly enhance check point blockade immunotherapy of patients with advanced bladder cancer, 2019.07-2023.06, $1,037,215 (Each year).

3) Department of Defense (DOD), W81XWH-19-1-0159, Novel nano-photo-immunotherapy against ovarian cancer, 2019.06-2022.06, $234,000 (Each year).

4) National Cancer Institute (NCI), 5R01CA115483-13, Therapeutic targeting agents for ovarian cancer, 2015.01-2021.04, $334,535  (Each year).

5) National Institute of Biomedical Imaging and Bioengineering (NIBIB), 2R01EB012569-09, Targeting nanotherapeutics against murine and feline oral cancer, 2010.12-2021.05, $518,074 (Each year).